Amgen 2010 Annual Report Download - page 55

Download and view the complete annual report

Please find page 55 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Rilotumumab (AMG 102)
Rilotumumab (AMG 102) is a fully human monoclonal antibody that blocks the action of hepatocyte growth
factor/scatter factor. It is being investigated as a cancer treatment.
Results from a study in mCRC in combination with Vectibix»were reported at a meeting in January 2011.
Phase 2 combination studies with rilotumumab (AMG 102) in the gastric, prostate, mCRC and small cell lung
cancer settings continue.
Human Resources
As of December 31, 2010, Amgen had approximately 17,400 staff members, which includes approximately
300 part-time staff members. There can be no assurance that we will be able to continue attracting and retaining
qualified personnel in sufficient numbers to meet our needs. None of our staff members are covered by a collective
bargaining agreement, and we have experienced no work stoppages. We consider our staff relations to be good.
Trade secret protection for our unpatented confidential and proprietary information is important to us. To
protect our trade secrets, we generally require our staff members, material consultants and scientific advisors to
execute confidentiality agreements upon commencement of employment or a consulting relationship with us.
However, others could either develop independently the same or similar information or obtain access to our
information.
Executive Officers of the Registrant
The executive officers of the Company as of February 11, 2011 are as follows:
Mr. Kevin W. Sharer, age 62, has served as a director of the Company since November 1992. Mr. Sharer has
been the Company’s Chief Executive Officer since May 2000 and has also been Chairman of the Board of Directors
since January 2001. From May 2000 to May 2010, Mr. Sharer also served as the Company’s President. From
October 1992 to May 2000, Mr. Sharer served as President and Chief Operating Officer of the Company. From
April 1989 to October 1992, Mr. Sharer was President of the Business Markets Division of MCI Communications
Corporation. From February 1984 to March 1989, Mr. Sharer held numerous executive capacities at General
Electric Company (“GE”). Mr. Sharer is a director of Chevron Corporation and Northrop Grumman Corporation.
He is Chairman of the Board of the Los Angeles County Museum of Natural History.
Mr. David W. Beier, age 62, became Senior Vice President, Global Government and Corporate Affairs in
March 2008. He joined the Company in 2003 as Senior Vice President, Global Government Affairs. Previously,
Mr. Beier was a partner with the law firm of Hogan and Hartson in Washington, D.C. From 1998 to early 2001,
Mr. Beier served as Chief Domestic Policy Advisor to the Vice President of the United States. He also held positions
as Vice President of Government Affairs and Public Policy for Genentech and staff counsel in the U.S. House of
Representatives. Mr. Beier is a director of ARYx Therapeutics, Inc.
Dr. Fabrizio Bonanni, age 64, became Executive Vice President, Operations in August 2007. He has served as
Senior Vice President, Manufacturing of the Company since 2004. Dr. Bonanni joined the Company in 1999 as
Senior Vice President, Quality and Compliance, and in June 2001 he also became the Corporate Compliance
Officer. Previously, Dr. Bonanni held various management positions at Baxter International, Inc. from 1974 to 1999,
including positions as Corporate Vice President, Regulatory and Clinical Affairs and Corporate Vice President,
Quality System.
Mr. Robert A. Bradway, age 48, became President and Chief Operating Officer of Amgen in May 2010.
Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy and served as Executive Vice
President and Chief Financial Officer from April 2007 to May 2010. Prior to joining the Company, he was a
Managing Director at Morgan Stanley in London where he had responsibility for the firm’s banking department and
corporate finance activities in Europe. Mr. Bradway joined Morgan Stanley in New York as a health care industry
investment banker in 1985 and moved to London in 1990 where he served as head of the firm’s international health
care investment banking activities until assuming broader corporate finance management responsibilities.
39